BiotechTube

ASP8062 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia

Trial Timeline

May 8, 2017 → Mar 6, 2018

NCT ID
NCT03092726

About ASP8062 + Placebo

ASP8062 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT03092726. Target conditions include Fibromyalgia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT05096117Phase 2Completed
NCT03183739Phase 1Completed
NCT03092726Phase 2Completed

Competing Products

20 competing products in Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
DS-5565 + PlaceboDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
ASP0819 + PlaceboAstellas PharmaPhase 2
52
DuloxetineShionogiPhase 3
77
Duloxetine 60 mg + PlaceboShionogiPhase 3
77
zonisamideEisaiApproved
85
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
DuloxetineEli LillyApproved
85
duloxetine hydrochloride + placeboEli LillyApproved
85
duloxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
Treatment for FibromyalgiaEli LillyPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77
Eszopiclone + placeboSumitomo PharmaApproved
85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85